-transparent.png){kind=logo}
The cholecystokinin (CCK) antagonist, proglumide, administered chronically (41.0-53.5 mg/kg per day, 14 days) to rats via osmotic mini-pumps, produced a significant 13% increase in the number of [3H]spiperone labeled binding sites (Bmax) in the striatum. There was no associated change in the affinity (Kd) of [3H]spiperone for the striatal binding sites. Given chronically at lower dose levels (10.4-13.6 or 21.8-29.8 mg/kg per day), or acutely in doses of 10, 20 or 40 mg/kg s.c., proglumide failed to alter the binding of [3H]spiperone to rat striatal tissue. These data indicate long-term proglumide administration increases the number of binding sites for [3H]spiperone, thought to be a ligand for dopamine D-2 receptors.
A J Bean, and
W J Baldy, and
G E Martin
August 1979,
Brain research,
A J Bean, and
W J Baldy, and
G E Martin
August 1978,
Life sciences,
A J Bean, and
W J Baldy, and
G E Martin
January 1991,
Journal of receptor research,
A J Bean, and
W J Baldy, and
G E Martin
August 1987,
Brain research,
A J Bean, and
W J Baldy, and
G E Martin
March 1984,
European journal of pharmacology,
A J Bean, and
W J Baldy, and
G E Martin
January 1983,
Proceedings of the Western Pharmacology Society,
A J Bean, and
W J Baldy, and
G E Martin
January 1999,
Neurobiology of aging,
A J Bean, and
W J Baldy, and
G E Martin
January 1981,
Journal of neurochemistry,
A J Bean, and
W J Baldy, and
G E Martin
July 1979,
European journal of pharmacology,
A J Bean, and
W J Baldy, and
G E Martin
March 1985,
Biulleten' eksperimental'noi biologii i meditsiny,
